Celltrion Pharm, Inc. (068760.KQ)
- Previous Close
91,900.00 - Open
90,200.00 - Bid --
- Ask --
- Day's Range
88,000.00 - 90,600.00 - 52 Week Range
57,714.29 - 133,300.00 - Volume
138,627 - Avg. Volume
326,613 - Market Cap (intraday)
3.715T - Beta (5Y Monthly) 0.40
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 10, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals and general pharmacies. Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju-si, South Korea.
www.celltrionph.com--
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Related News
Performance Overview: 068760.KQ
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 068760.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 068760.KQ
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
9.47%
Return on Assets (ttm)
3.41%
Return on Equity (ttm)
8.91%
Revenue (ttm)
274.73B
Net Income Avi to Common (ttm)
26.03B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
34.63B
Total Debt/Equity (mrq)
63.34%
Levered Free Cash Flow (ttm)
-20.1B